Spots Global Cancer Trial Database for vidaza
Every month we try and update this database with for vidaza cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma | NCT01983969 | Advanced Cancer... Lymphoma | Azacitidine Vorinostat Gemcitabine Busulfan Melphalan Dexamethasone Caphosol Glutamine Pyridoxine Rituximab | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation. | NCT02017457 | Acute Myelogeno... Myelodysplastic... | Donor lymphocyt... Azacytidine | 18 Years - | University Hospital of Mont-Godinne | |
| Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | NCT00948064 | Leukemia | Vorinostat Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer | NCT00529022 | Solid Tumors | Azacitidine Valproic Acid Carboplatin | - | M.D. Anderson Cancer Center | |
| Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML) | NCT02447666 | Myelodysplastic... Leukemia, Myelo... | Azacitidine | 1 Month - 18 Years | Celgene | |
| Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) | NCT02829840 | Leukemia FLT3-Mutated Ac... FLT3-Mutated Hi... | Ponatinib 5-azacytidine Phone Calls | 18 Years - | M.D. Anderson Cancer Center | |
| Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS | NCT02018926 | Myelodysplastic... | Mocetinostat Azacitidine | 18 Years - | Mirati Therapeutics Inc. | |
| Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS | NCT02018926 | Myelodysplastic... | Mocetinostat Azacitidine | 18 Years - | Mirati Therapeutics Inc. | |
| Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | NCT00666497 | Acute Myeloid L... Myelodysplastic... | Azacitidine MGCD0103 MGCD0103 | 60 Years - | Mirati Therapeutics Inc. | |
| Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML) | NCT01074047 | Acute Myeloid L... | Azacitidine Conventional Ca... | 65 Years - | Celgene | |
| Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) | NCT01201811 | Myelodysplastic... | Azacitidine | 18 Years - | Celgene | |
| Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk | NCT00906334 | Myelodysplastic... | ON 01910.Na ON 01910.Na | 18 Years - | Traws Pharma, Inc. | |
| Azacytidine and Valproic Acid in Patients With Advanced Cancers | NCT00496444 | Advanced Cancer... | Azacitidine Valproic Acid | 2 Years - | M.D. Anderson Cancer Center | |
| Registry on Hypomethylating Agents in Myeloid Neoplasms | NCT01595295 | Chronic Myelomo... Myelodysplastic... Acute Myeloid L... | non interventio... | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome | NCT01254890 | Leukemia | Azacitidine Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk | NCT01720225 | Leukemia | Decitabine Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) | NCT00887068 | Leukemia AML MDS | Azacitidine | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma | NCT02701673 | Lymphoma | Busulfan Caphosol Glutamine Pyridoxine Belinostat Azacitidine Gemcitabine Melphalan Stem Cell Trans... | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) | NCT02469415 | Leukemia | Pacritinib 5-azacitidine Decitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Phase II 5-Azacytidine Plus VPA Plus ATRA | NCT00326170 | Myelodysplastic... Acute Myelogeno... | 5-Azacytidine (... Valproic Acid All-Trans Retin... | 3 Years - | M.D. Anderson Cancer Center | |
| Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML) | NCT02096042 | Leukemia | Brentuximab Ved... 5-Azacytidine | 18 Years - | M.D. Anderson Cancer Center | |
| PKC412 and 5-Azacytidine | NCT01202877 | Leukemia | 5-azacytidine PKC412 | 18 Years - | M.D. Anderson Cancer Center | |
| Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT) | NCT00350818 | Myelodysplastic... Leukemia | Azacitidine | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Azacytidine and Valproic Acid in Patients With Advanced Cancers | NCT00496444 | Advanced Cancer... | Azacitidine Valproic Acid | 2 Years - | M.D. Anderson Cancer Center | |
| Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk | NCT01720225 | Leukemia | Decitabine Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma | NCT02701673 | Lymphoma | Busulfan Caphosol Glutamine Pyridoxine Belinostat Azacitidine Gemcitabine Melphalan Stem Cell Trans... | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation | NCT02196857 | Leukemia | Azacytidine Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) | NCT02599649 | Leukemia | Lirilumab Nivolumab Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) | NCT02599649 | Leukemia | Lirilumab Nivolumab Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome | NCT02117219 | Myelodysplastic... | MEDI4736 Evalua... VIDAZA tremelimumab | 18 Years - 99 Years | MedImmune LLC | |
| Azacitidine and CAPOX in Metastatic Colorectal Cancer | NCT01193517 | Colorectal Canc... | Azacitidine Capecitabine Oxaliplatin Azacitidine MTD | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome | NCT02117219 | Myelodysplastic... | MEDI4736 Evalua... VIDAZA tremelimumab | 18 Years - 99 Years | MedImmune LLC | |
| Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine | NCT01519011 | Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... | oral azacitidin... oral azacitidin... | 18 Years - | Celgene | |
| Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS) | NCT01542684 | Leukemia | Azacytidine GM-CSF | 18 Years - | M.D. Anderson Cancer Center | |
| Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer | NCT01167816 | Pancreatic Canc... | Vidaza | 18 Years - | University of Oklahoma | |
| Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | NCT02223052 | Hematological N... Non-Hodgkin's L... Hodgkin's Lymph... Lymphoma Multiple Myelom... Acute Myeloid L... Leukemia Myelodysplastic... Neoplasms Melanoma Breast Cancer Metastatic Brea... Non-Small Cell ... Small Cell Lung... Renal Cell Carc... Glioblastoma Mu... Osteosarcoma Sarcoma Thyroid Cancer Genitourinary | CC-486 Vidaza | 18 Years - | Celgene | |
| Registry on Hypomethylating Agents in Myeloid Neoplasms | NCT01595295 | Chronic Myelomo... Myelodysplastic... Acute Myeloid L... | non interventio... | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies | NCT00996515 | Advanced Solid ... | 5-azacytidine, ... Erlotinib PO an... | 19 Years - | New Mexico Cancer Care Alliance | |
| Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients | NCT00382590 | Acute Myelogeno... Myelodysplastic... Leukemia | 5-Azacytidine Ara-C Valproic Acid (... | 60 Years - | M.D. Anderson Cancer Center | |
| Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy | NCT01209520 | Lung Cancer Non Small Cell ... Hypermethylatio... | Cisplatin Carboplatin Paclitaxel Vidaza Tumor Specimen ... Blood Sample fo... Vinorelbine Docetaxel Pemetrexed | 18 Years - | University of Miami | |
| Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) | NCT02829840 | Leukemia FLT3-Mutated Ac... FLT3-Mutated Hi... | Ponatinib 5-azacytidine Phone Calls | 18 Years - | M.D. Anderson Cancer Center | |
| Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy | NCT01209520 | Lung Cancer Non Small Cell ... Hypermethylatio... | Cisplatin Carboplatin Paclitaxel Vidaza Tumor Specimen ... Blood Sample fo... Vinorelbine Docetaxel Pemetrexed | 18 Years - | University of Miami | |
| Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer | NCT01167816 | Pancreatic Canc... | Vidaza | 18 Years - | University of Oklahoma | |
| Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea | NCT02137629 | Myelodysplastic... | Vidaza® | 18 Years - | Celgene | |
| Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea | NCT02137629 | Myelodysplastic... | Vidaza® | 18 Years - | Celgene | |
| Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA | NCT01993641 | Myelodysplastic... MDS | pracinostat Azacitidine Decitabine | 18 Years - | Helsinn Healthcare SA | |
| Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome | NCT01254890 | Leukemia | Azacitidine Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer | NCT00529022 | Solid Tumors | Azacitidine Valproic Acid Carboplatin | - | M.D. Anderson Cancer Center | |
| Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) | NCT00887068 | Leukemia AML MDS | Azacitidine | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia. | NCT02450877 | Leukemia, Myelo... | Azacitidine Control Arm | 3 Months - 21 Years | Celgene | |
| 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia | NCT00413478 | Chronic Lymphoc... Leukemia | 5-Azacytidine | 18 Years - | M.D. Anderson Cancer Center | |
| Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer | NCT00901537 | Non-small Cell ... Squamous Cell C... | Azacitidine and... | 18 Years - | Loma Linda University | |
| Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer | NCT00529022 | Solid Tumors | Azacitidine Valproic Acid Carboplatin | - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
